Inhibikase Therapeutics
Atlanta
About Inhibikase Therapeutics
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $225.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:IKT
- Website: inhibikase.com
- Phone: 617-936-0184
Industries & Categories
Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inhibikase-therapeutics-66030 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.